1996 to 2013 Saw Large Increase in Diabetes Spending
Increased spending per encounter has been the biggest driver of overall rise in spending.
Diagnosis & Disease Information
The CVS/Aetna merger and the future of primary care
Both CVS and Aetna care deeply about the prices of pharmaceuticals, but they are hoping to maximize company profits, not consumer savings.
About 1 in 3 drugs have safety concerns after FDA approval
Almost one third of the new therapeutics approved by the FDA between 2001 and 2010 were affected by a postmarket safety event.
American College of Physicians recommends prescribing generic medications
Clinicians should prescribe generic medications over brand-name drugs when they can because the generics are less expensive and molecularly identical.
Clinician access on the decline for pharmaceutical reps
A new survey indicates that pharmaceutical representatives have restricted access to over half of clinicians.
Improved control of seizures
Fycompa is indicated to treat partial-onset seizures in patients aged 12 years and older.
Breakthrough therapy for HCV infection
Sofosbuvir is indicated for use with other medications as part of an antiviral treatment regimen for chronic hepatitis C infection.
GSK ends physician speaking fees
Pharmaceutical giant first drug maker to adopt such a policy and may encourage others to follow suit.
FDA investigating death of two patients on Zyprexa
The FDA is looking into the cause of death of two patients who died several days after receiving injections of Zyprexa Relprevv.
Myrbetriq safe, effective alternative for OAB
High discontinuation rates with traditional second-line therapies suggest more overactive bladder treatment options are needed.
- Loading...
Loading...
Next post in AAPA 2013
Loading... 
Loading...